The European Society for Medical Oncology (ESMO) hails the findings from a large international breast cancer study published today in The Oncologist, highlighting the need for regulators and hospital authorities to avoid unnecessary delays in approving clinical trials. In the research paper, corresponding author Dr. Otto Metzger Filho, from the Dana-Farber Cancer Institute, and colleagues investigated the time that elapsed between the various regulatory steps, including approval from national regulatory authorities, ethics committees and review boards within participating institutions, before researchers could start treating patients in the Phase III ALTTO trial. Read more here.
Study mentioned: Metzger-Filho O, et al. Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience. The Oncologist first published on January 28, 2013.
No comments:
Post a Comment